Detalhe da pesquisa
1.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol
; 20(10): 563-578, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126311
2.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med
; 381(1): 13-24, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31150574
3.
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Int J Urol
; 28(3): 280-287, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33295007
4.
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
J Clin Oncol
; 39(20): 2294-2303, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914595
5.
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Leukemia
; 35(1): 62-74, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32203138
6.
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
J Clin Oncol
; 27(23): 3842-8, 2009 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19528372